The document summarizes a report by IQ4I Research & Consultancy on the global interventional oncology market. Some key points: - The global interventional oncology market is estimated to reach $2.1 billion by 2026, growing at a high single-digit CAGR from 2019 to 2026. - Embolization currently occupies the highest market share but ablation is the fastest growing segment. - The liver cancer application segment currently generates the highest revenue but brain & spine cancers are growing the fastest. - North America currently dominates the market but Asia-Pacific is growing the fastest, driven by factors like an aging population and increased healthcare access.

1. IQ4I Research & Consultancy Pvt. Ltd. Page 1
Interventional Oncology Global Market
–Forecast to 2026
Interventional Oncology Global Market estimated to be worth $2.1 billion by
2026
IQ4I Research & Consultancy published a new report on “Interventional Oncology
Global Market – Forecast To 2026” This report analyzes and studies the overall market,
major Drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific
and Rest of the World.
IQ4I’s Report Contains 112 market data tables and 111 figures spread through 404
pages and an exhaustive TOC on “Interventional Oncology Global Market”, [By
Products (Ablation (Microwave Ablation, Cryoablation Radiofrequency Ablation and
others), and Embolization (Radio Embolization and Non-Radio Embolization),
Embolization by Procedure (TARE/SIRT, TACE, DEB TACE, Bland/TAE), By
Application (Liver Cancer, Kidney Cancer, Lung Cancer, Brain & Spine Cancer,
Prostate Cancer, Uterine Fibroid and other Cancers), By End-Users (Hospitals,
Ambulatory Surgical Centers and Academics & Research Institutes), By Region (North
America, Europe, Asia-Pacific and Rest of the World)].
Interventional oncology (IO) is a subspecialty field of interventional radiology (IR) that deals
with the diagnosis, manages and treat the patients with liver, kidney, prostate, lung and other
forms of cancer, utilizes imaging guidance to perform minimally invasive procedure.
Compared to conventional procedures such as external radiation therapy, chemotherapy,
pharmaceutical, and immunotherapy, minimally invasive interventional oncology techniques
are usually safer and less painful than open surgery, results in fewer complications and
hospital stays and are less costly. IO techniques are being studied in combination with
targeted therapies and immunotherapies in the hope of improving outcomes in patients with
cancer.
The interventional oncology global market is expected to grow at a high-single digit CAGR
from 2019 to 2026 to reach $2,119.4 million by 2026. Some of the factors driving the market
are increasing prevalence of cancer cases, growing adoption of minimally invasive
procedures, increasing geriatric population, technological advancements in the field of
interventional oncology and expansion in the emerging markets.
The interventional oncology market by product is segmented into ablation and embolization.
The embolization segment occupies the highest revenue 2019 and it is expected to grow at
a double-digit CAGR from 2019 to 2026. The ablation segment is the fastest-growing
segment with a high single digit CAGR from 2019 to 2026. Among ablation by product type,
the microwave ablation accounts for the highest in 2019 and it is expected to grow at a
double digit CAGR from 2019 to 2026. The other ablation (laser ablation and Irreversible
electroporation) segment is the fastest-growing segment with a high teen CAGR from 2019

2. IQ4I Research & Consultancy Pvt. Ltd. Page 2
Interventional Oncology Global Market
–Forecast to 2026
to 2026. Among embolization by product type, the non-radioembolization accounts for the
highest revenue in 2019 and it is expected to grow at a mid-single digit CAGR from 2019 to
2026. The radioembolization segment is the fastest-growing segment with a high single digit
CAGR from 2019 to 2026. The embolization segment by procedure, transarterial
radioembolization (TARE) segment occupies the highest revenue in 2019 and it is expected
to grow at a high single digit CAGR from 2019 to 2026.
Among interventional oncology applications, the liver cancer segment accounts for the
highest revenue in 2019 and it is expected to grow at a mid-single digit CAGR from 2019 to
2026. The brain & spine cancer segment is the fastest-growing segment with a double digit
CAGR from 2019 to 2026. Among end-users, the hospital segment occupies the highest
revenue in 2019 and it is expected to grow at a high single digit CAGR from 2019 to 2026.
The ambulatory surgical centers segment is the fastest-growing segment with a high single
digit CAGR from 2019 to 2026.
The interventional oncology market by region is segmented as North America, Europe, Asia-
Pacific and the Rest of the world. North America accounts for the highest revenue in 2019
and it is expected to grow at a mid-single digit CAGR from 2019 to 2026 mainly due to
adoption of the technological advancements, increasing incidences of cancer, increase in
training institutes for interventional oncology, increasing demand for minimally invasive
surgeries, favorable reimbursements, product launches, skilled personnel, and strong
product pipeline. The Asia-Pacific region is the fastest-growing region with a double digit
CAGR from 2019 to 2026 due to increasing geriatric population, increased healthcare
facilities, increasing incidence of cancer, increasing awareness about interventional
oncology and low-cost for the surgery are driving the market.
Considering the attractiveness of the interventional oncology market, several venture
capitalists are aggressively investing. Globally, funding is more concentrated on the prostate,
liver and other types of cancers. For instance, in April 2019 ABK Biomedical, Inc. received a
fund amount of $xx million from F-Prime Capital and Varian Medical Systems. The company
will use the funding for continued focused product development of the Eye90 microsphere
which is designed for transarterial radioembolization (TARE) and Easi-Vue microspheres for
bland embolic/transarterial embolization (TAE) for the treatment of hypervascular tumors.
Similarly, interventional oncology clinical trials data indicate that in the U.S., 38.5% clinical
trials are in phase 3 stage, 50.0% clinical trials are in phase-2, and 11.5% clinical trials are in
phase-1. The majority of clinical trials are focused on liver cancer, colorectal cancer and

3. IQ4I Research & Consultancy Pvt. Ltd. Page 3
Interventional Oncology Global Market
–Forecast to 2026
kidney cancer (renal cancer). There is a steady increase in the number of clinical trials
performed year-on-year which may result in the launch of several new products in the
coming years, which is expected to drive the interventional oncology market further.
According to IQ4I analysis, the average number of units used for procedure performed by
radiofrequency ablation (RFA) is estimated to be xx units (ASP- $xx), the average number of
units used for procedure performed by microwave ablation (MWA) is estimated to be xx units
(ASP- $xx) and the average number of units used for procedure performed by cryoablation is
estimated to be xx units (ASP-xx) respectively. The total number of ablation devices globally
is estimated to be xx in 2019 and is expected to grow at a high single digit CAGR from 2019
to 2026.
Interventional Oncology market has a huge opportunity for existing players and new
entrants. The ablation and embolization manufacturers can develop and launch new
products to gain the sparely occupied market. According to IQ4I analysis, it is estimated that
794,108 people are diagnosed with liver cancer globally. In 2019, the total number of liver
cancer treated by interventional oncology is estimated to be xx, indicating a penetration rate
of xx% with an opportunity of xx% in the market. Similarly, it is estimated that 882,738
people are diagnosed with brain & spine cancer globally. In 2019, the total number of brain &
spine cancer treated by interventional oncology is estimated to be xx indicating a penetration
rate of xx% with an opportunity of xx% in the market.
Some of the companies are coming up with technological advancements to maintain their
leadership status in the interventional oncology market. For instance, AngioDynamics, Inc.
(U.S.) a leading provider of innovative, minimally invasive medical devices has developed
the Nanoknife system, received USFDA approval in May 2019. The system is a unique,
minimally invasive technique that has been used to successfully treat focal prostate lesions
through irreversible electroporation.
The interventional oncology companies mainly focus on expansion, new product launches,
and acquisitions to be competent and gain access to new technologies both in existing and
new market areas. For instance, Sirtex Medical (Australia) collaborated with MIM Software,
Inc. (U.S.) a leading global provider of practical imaging solutions in the fields of radiation
oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. The partnership
advances innovation and increases the precision of liver-directed oncology therapies for
patients.

4. IQ4I Research & Consultancy Pvt. Ltd. Page 4
Interventional Oncology Global Market
–Forecast to 2026
In December 2019, the Ministry of Health and Family Welfare delivered registration for the
Guerbet’s innovative conventional Trans-Arterial ChemoEmbolization (cTACE) mixing and
injection system, Vectorio in India. Victorio is a set of Lipiodol resistant medical devices
including syringes, patented stopcock and sampling devices. Vectorio is dedicated to mixing
and delivering Lipiodol Ultra Fluid & anticancer drugs during cTACE procedure in adults with
known, intermediate-stage hepatocellular carcinoma (HCC).
The interventional oncology global market is consolidated with the top five players occupying
xx% of the market share and the remaining xx% of the market is occupied by other players.
Some of the major players in interventional oncology market include Medtronic Plc (Ireland),
Sirtex Medical (Australia), Boston Scientific Corporation (U.S.), Guerbet (France), Merit
Medical System (U.S.), Varian Medical System, Inc. (U.S.), Terumo Corporation (Japan),
Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).

5. IQ4I Research & Consultancy Pvt. Ltd. Page 5
Interventional Oncology Global Market
–Forecast to 2026
Reasons for buying this report:
 Interventional Oncology global market is projected to reach $2,119.4 million by 2026
at a high single digit CAGR.
 Identification and analysis of interventional oncology market segments by product,
application, end-users and geography.
 Revenue forecast of interventional oncology market and strategic analysis of each
sub segment with respect to segmental growth trends.
 Identification of major market trends, Porter's model, factors driving and restraining
interventional oncology market.
 Analysis of Market penetration by application, global procedure volume by product
type, analysis of average selling price (ASP), ablation number of devices by region,
regulatory approval analysis of major products, reimbursement scenario, funding
scenario, clinical trials, supply chain, market share analysis of interventional
oncology, ablation and embolization, company comparison table by products and
application.
 Analysis of the opportunities for stakeholders by identifying the high-growth
segments of the market.
 Revenue forecast of interventional oncology market with respect to North America
(U.S., Rest of North America), Europe (Germany, France, Italy and Rest of Europe),
Asia-pacific (China, Japan, Australia and Rest of Asia-Pacific) and Rest of the World
(Brazil, Rest of Latin America and Middle East & Others).
 Profiles of major players in interventional oncology market and analysis of their
product offerings, financial revenue, business strategies, SWOTs and market shares.

6. IQ4I Research & Consultancy Pvt. Ltd. Page 6
Interventional Oncology Global Market
–Forecast to 2026
FIGURE 1
INTERVENTIONAL ONCOLOGY GLOBAL MARKET SEGMENTATION
Product Application End-User Region
Ablation Embolization
RF Ablation
Microwave
Ablation
Cryoablation
Other
Ablations
Procedure
Type
Product
Type
Radio
Embolization
Non Radio
Embolization
TARE/SIRT
TACE
DEB TACE
Bland/TAE
I.O.
Application
Embolization
Application
Ablation
Application
Liver
Kidney
Lung
Brain & Spine
Prostate
Uterine
Fibroid
Others
Liver
Kidney
Lung
Brain & Spine
Prostate
Others
Liver
Lung
Prostate
Uterine
Fibroid
Others
Hospitals
ASC
Academics &
Research
North
America
Europe
APAC
ROW
Interventional Oncology Global Market